EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment

Pablo Miranda iD, Luis Ignacio Tártara iD, Analía Castro iD, Patricia Zimet iD, Ricardo Faccio iD, Santiago Daniel Palma iD, Álvaro W Mombrú iD, Helena Pardo iD

Pharmaceutics · 13.09.2025 · 17 (9) · 1191

DOI: 10.3390/pharmaceutics17091191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 13.09.2025. Verfasst von Pablo Miranda und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Nanotecnología, Instituto Polo Tecnológico de Pando, Facultad de Química, Universidad de la República, Canelones 91000, Uruguay. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANII - Agencia Nacional de Investigación, ANII–Agencia Nacional de Investigación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: We report the development of a novel intraocular sustained-release implantable pharmaceutical formulation, designed to be placed in the anterior chamber of the eye after cataract surgery. The device is intended to reduce postoperative inflammation, and to prevent opportunistic bacterial infections that may lead to endophthalmitis.

Methods

The implants were produced via hot-melt extrusion, using a twin-screw extruder to process a homogeneous mixture of polylactide-co-glycolic acid, moxifloxacin hydrochloride (MOX HCl) and dexamethasone (DEX). Quality control tests included drug content determination, release rate profile evaluation, and several instrumental characterization techniques (scanning electron microscopy (SEM), confocal Raman microscopy, differential scanning calorimetry, and X-ray diffraction). Long-term and accelerated stability tests were also performed, following ICH guidelines. Sterilization was achieved by exposing samples to gamma radiation. In vivo exploratory studies were carried out in healthy rabbits to evaluate the safety and overall performance of the implantable formulation.

Results

In terms of quality control, drug content was found to be homogeneously distributed throughout the implants, and it also met the label claim. In vitro release rate was constant for MOX HCl, but non-linear for DEX, increasing over time. In vivo preliminary tests showed that the inserts completely biodegraded within approximately 20 days. No clinical signs of anterior segment toxic syndrome or statistically significant intraocular pressure differences were found between treatment and control groups.

Conclusions

The implants developed in this study can act as sustained-release depots for the delivery of both DEX and MOX HCl, and are biocompatible with ocular structures.

Schlagwörter

Stichwörter der Autor:innen

cataractdexamethasoneendophthalmitisintraocular implantsmoxifloxacin

Autor:innen und Institutionen

  • Laboratorio de Nanotecnología, Instituto Polo Tecnológico de Pando, Facultad de Química, Universidad de la República, Canelones 91000, Uruguay.
  • Cátedra de Física Biomédica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba X5016JXA, Argentina.
  • Unidad de Investigación y Desarrollo en Tecnología Farmacéutica, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba X5016JXA, Argentina.
  • Área Física, Facultad de Química, Universidad de la República, Montevideo 11800, Uruguay.

ORCID-Profile: Pablo Miranda, Luis Ignacio Tártara, Analía Castro, Patricia Zimet, Ricardo Faccio, Santiago Daniel Palma, Álvaro W Mombrú, Helena Pardo

Förderung

  • ANII - Agencia Nacional de Investigación
  • ANII–Agencia Nacional de Investigación

Zitieren

APA

Miranda, P., Tártara, L. I., Castro, A., Zimet, P., Faccio, R., Palma, S. D., Mombrú, Á. W., & Pardo, H. (2025). Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment. Pharmaceutics, 17(9), 1191. https://doi.org/10.3390/pharmaceutics17091191

Vancouver

Miranda P, Tártara LI, Castro A, Zimet P, Faccio R, Palma SD, et al. Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment. Pharmaceutics. 2025;17(9):1191. doi:10.3390/pharmaceutics17091191

BibTeX
@article{Miranda2025,
  author = {Miranda, Pablo and Tártara, Luis Ignacio and Castro, Analía and Zimet, Patricia and Faccio, Ricardo and Palma, Santiago Daniel and Mombrú, Álvaro W and Pardo, Helena},
  title = {Sustained-Release Biodegradable Intracameral Implants Containing Dexamethasone and Moxifloxacin: Development and In Vivo Primary Assessment},
  journal = {Pharmaceutics},
  year = {2025},
  volume = {17},
  number = {9},
  pages = {1191},
  doi = {10.3390/pharmaceutics17091191}
}
Kostenlos starten →